Analyst Price Target is $78.44
▲ +72.79% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is $78.44, with a high forecast of $91.00 and a low forecast of $60.00. The average price target represents a 72.79% upside from the last price of $45.40.
Current Consensus is
The current consensus among 10 polled investment analysts is to buy stock in BridgeBio Pharma. This Buy consensus rating has held steady for over two years.
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.